Efficacy and safety of oxymetazoline cream 1

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.

ATX-101 for reduction of submental fat: A phase III randomized controlled trial Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients Patrizia Weber, MD, S. Morteza Seyed Jafari,

Facial adenocarcinoma treated with intra-arterial chemotherapy

Efficacy of the long-pulsed 1064-nm neodymium:yttrium-aluminum-garnet laser (LPND) (rejuvenation mode) in the treatment of papulopustular rosacea (PPR):

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Baldness reversed by chemotherapy

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker Chia-Chi Hsu, MD,

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

David T. Pompei, Pharm D, Kameron S. Rezzadeh, BS, Kate V

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Applying for dermatology residency is difficult and expensive

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Chauncey C. Caldwell, MD, Sami K. Saikaly, MD, Robert P

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,

Infectious rash after riding elephants

Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial Lauren Okon, MD, Misha Rosenbach, MD, Michael.

Ethan T. Routt, BA, Jacob O. Levitt, MD

Lip edema Journal of the American Academy of Dermatology

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Stefan Tukaj, PhD, Detlef Zillikens, MD, Michael Kasperkiewicz, MD

Hugh Gloster, MD, Chesahna Kindred, MBA

Seasonal patterns in alopecia areata, totalis, and universalis

Efficacy and safety of calcipotriol/betamethasone dipropionate ointment for the treatment of simple onycholysis: An open-label study Jung-Min Park, MD,

A comparison of postprocedural wound care treatments: Do antibiotic-based ointments improve outcomes? Zoe D. Draelos, MD, FAAD, Ronald L. Rizer, PhD,

Medicaid acceptance among pediatric dermatologists

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma Howard Sofen, MD,

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Lack of the effect of topical vitamin K on bruising after mechanical injury R.K Kovács, MD, L Bodai, A Dobozy, MD, PhD, DSC, L Kemény, MD, PhD, DSC Journal.

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne Jerry Tan, MD, Diane Thiboutot, MD, Georg Popp,

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Anastasia O. Kurta, DO, Daisy Dai, PhD, Eric S

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial Diane Thiboutot, MD, David.

Presentation transcript:

Efficacy and safety of oxymetazoline cream 1 Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial Zoe Diana Draelos, MD, Michael H. Gold, MD, Robert A. Weiss, MD, Leslie Baumann, MD, Steven K. Grekin, DO, Deanne Mraz Robinson, MD, Steven E. Kempers, MD, Nancy Alvandi, PhD, Emily Weng, ScD, MBA, David R. Berk, MD, Gurpreet Ahluwalia, PhD Journal of the American Academy of Dermatology Volume 78, Issue 6, Pages 1156-1163 (June 2018) DOI: 10.1016/j.jaad.2018.01.027 Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Efficacy. Percentage of patients experiencing a composite 2-grade or greater improvement from baseline (before the dose on day 1) in Clinician Erythema Assessment (CEA) and Subject Self-Assessment for rosacea facial redness (SSA) (composite success). Analysis was based on observed cases at each time point in the modified intent-to-treat population. Journal of the American Academy of Dermatology 2018 78, 1156-1163DOI: (10.1016/j.jaad.2018.01.027) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Oxymetazoline efficacy over 6 hours after the dose in a female (A) and a male (B) patient with moderate-to-severe persistent erythema associated with rosacea. On the basis of a 2-grade or greater improvement from baseline (predose on day 1) on both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for rosacea facial redness (SSA), the female oxymetazoline-treated patient was considered a responder at hour 3 at week 26 and hour 6 at week 52 (A), and the male patient was a responder at hour 6 at week 26 and week 52 (B). One star indicates a 2-grade or greater improvement from baseline in CEA or SSA; 2 stars indicate a 2-grade or greater improvement from baseline in both CEA and SSA. Journal of the American Academy of Dermatology 2018 78, 1156-1163DOI: (10.1016/j.jaad.2018.01.027) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions